You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲南白藥(000538.SZ):受讓北大醫院、北腫研究所合作研發的PSMA靶向核藥相關專利
格隆匯 09-02 08:22

格隆匯9月2日丨雲南白藥(000538.SZ)公佈,近日,公司與北京大學第一醫院(簡稱“北大醫院”)、北京市腫瘤防治研究所(簡稱“北腫研究所”)簽訂《技術轉讓與合作開發協議》。北大醫院、北腫研究所將其合作研發的前列腺特異性膜抗原(PSMA)靶向核藥(簡稱“合作標的”)相關專利轉讓給公司(簡稱“該項目”),公司將在全球範圍內對合作標的進行研究開發、生產和商業化活動。

北大醫院、北腫研究所、雲南白藥有意在目前研發的基礎上繼續共同研發該項目,最終實現相關藥品的註冊和商業化。雲南白藥應向轉讓方支付總額為人民幣2000萬元的技術轉讓價款。各方同意,技術轉讓價款應按照里程碑事件進行付款。

當前,該合作標的在臨牀前研究階段已獲得部分研究成果,在研究者發起的臨牀試驗(IIT)中顯示出良好效果,並且已獲得相關專利授權。完成該合作標的受讓和引入後,公司中央研究院將按照新藥臨牀試驗申請(IND)申報要求啟動相關研究工作,該項目的開展有助於雲南白藥加快進軍核藥領域的步伐。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account